Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Erectile Dysfunction 4Pancreatic Neoplasms 3Head and Neck Neoplasms 3Neoplasms 2Neoplasm Metastasis 2Carcinoma 2Adenocarcinoma 2Urogenital Neoplasms 1Urinary Incontinence 1Sexual Dysfunction, Physiological 1Pyridoxine-dependent epilepsy 1Peripheral Nervous System Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neurotoxicity Syndromes 1Multiple Myeloma 1Mouth Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Glioblastoma 1Gastric Adenocarcinoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Astrocytoma 1Abdominal Cancer 1

Interventions

Acupuncture Therapy 10Exercise 7Cryotherapy 6Paclitaxel 5Glutamine 5Surveys and Questionnaires 3Duloxetine Hydrochloride 3Dexamethasone 3Bortezomib 3Acetylcysteine 3pembrolizumab 2enfortumab vedotin 2Thioctic Acid 2Tablets 2Sodium Chloride 2Saline Solution 2Physical Therapy Modalities 2Low-Level Light Therapy 2Lenalidomide 2Fish Oils 2Fatty Acids, Omega-3 2ziconotide 1sagopilone 1nicotinamide-beta-riboside 1nabilone 1glutamic acid diethyl ester 1eribulin 1allantoicase 1Yoga 1XELOX 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Peripheral Nervous System Diseases × Tadalafil × Clear all
NCT07333976 2026-01-12

o Tadalafil for Prevention of Docetaxel-Induced Peripheral Neuropathy in Prostate Cancer

Tri-Service General Hospital

Phase 2 Completed
90 enrolled

Peripheral Nervous System Diseases, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡